长期随访评估年轻女性及女童癌症患者卵巢组织冷冻保存的生育力保存标准
该队列研究纳入1996年1月1日至2020年4月30日苏格兰东南部638例18岁以下女性癌症患者,最终分析422例,评估爱丁堡筛选标准识别早发性卵巢功能不全(POI)风险的效果。接受卵巢组织冷冻保存(OTC)的37例中9例(24.3%)发生POI,未接受OTC的386例中11例(2.9%)发生POI,风险比为8.7(95%CI 3.6-21;P<0.0001)。结论认为该标准能准确识别POI高风险患者并适当提供OTC,但疾病复发需更强治疗仍是挑战。
要点
- 爱丁堡筛选标准可准确识别儿童癌症后POI高风险患者,并据此提供OTC。
- 接受OTC者POI风险显著高于未接受者(HR 8.7,95%CI 3.6-21;P<0.0001)。
- 需将生殖功能评估与记录纳入血液/肿瘤常规随访。
核心结论
- 爱丁堡筛选标准能准确识别POI高风险患者,可适当提供OTC及未来移植作为生育力保存手段。
- 儿童癌症后POI患病率低,但疾病复发需更强治疗仍是挑战。
- 研究强调血液/肿瘤随访中常规评估和记录生殖状态的重要性。
研究设计与样本
- 队列研究,纳入1996年1月1日至2020年4月30日苏格兰东南部所有18岁以下女性癌症患者。
- 共识别638例合格患者,排除12岁以下或12岁前死亡者,研究人群431例。
- 排除因POI或全垂体功能减退(无性腺毒性治疗史)以外原因使用激素避孕者9例,最终分析422例。
- 采用Kaplan-Meier法(以POI为事件)和Cox比例风险模型分析。
主要发现
- 431例患者诊断时中位年龄9.8岁,分析时中位年龄22.2岁。
- 142例生殖结局不可用,假设无POI,并进行了排除这些患者的亚组分析。
- 422例中,37例被提供OTC并25例成功实施;提供OTC的37例中9例(24.3%)发生POI,未提供OTC的386例中11例(2.9%)发生POI。
- 提供OTC者发生POI的风险显著更高(HR 8.7,95%CI 3.6-21;P<0.0001),排除结局未知者后仍显著(HR 8.1,95%CI 3.4-20;P<0.001)。
- 提供OTC并发生POI者均在原发病治疗后发生;未提供OTC者中5例(45.5%)在疾病复发治疗后发生POI。
关键数值与推荐
- 爱丁堡筛选标准基于计划癌症治疗和患者健康状况,用于识别POI高风险并符合OTC条件者。
- 提供OTC的37例中POI发生率24.3%(9/37),未提供OTC的386例中为2.9%(11/386)。
- 提供OTC者POI风险HR 8.7(95%CI 3.6-21;P<0.0001);排除结局未知者后HR 8.1(95%CI 3.4-20;P<0.001)。
临床怎么用
- 原文未据此给出具体临床推荐。
- 作者指出爱丁堡筛选标准仍是诊断时选择POI高风险者并适当提供OTC的稳健工具。
- 作者强调血液/肿瘤随访中应常规评估和记录生殖状态。
局限性
- 大量患者生殖结局未知,其中许多仍在随访但无生殖评估记录,可能引入偏倚。
- 患者人群相对年轻且部分病例随访时间短,需对该队列继续随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do the Edinburgh Selection Criteria correctly identify female cancer patients under the age of 18 who are at risk of premature ovarian insufficiency (POI) as candidates for ovarian tissue cryopreservation (OTC)? SUMMARY ANSWER: Patient assessment using these criteria accurately identifies those at risk of POI, who can be offered OTC and future transplantation as a means of fertility preservation. WHAT IS KNOWN ALREADY: Treatment for childhood cancer can have adverse consequences on future fertility; at the time of diagnosis, fertility risk assessment should be undertaken in order to identify patients to whom fertility preservation should be offered. The Edinburgh selection criteria, based on planned cancer treatment and patient health status, are utilized to identify those at high risk and therefore eligible for OTC. However, this procedure is not without risk and there are few data on the efficacy of the procedure in prepubertal patients. As such, long-term follow-up of reproductive outcomes is necessary, to ensure that OTC is being offered appropriately. STUDY DESIGN, SIZE, DURATION: Cohort study encompassing all females diagnosed with cancer under the age of 18 in South East Scotland, from 1 January 1996 to 30 April 2020. Patients were followed up for reproductive outcomes to assess for diagnosis of POI. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 638 eligible patients were identified; patients under the age of 12 or deceased before the age of 12 were excluded from the study, leaving a study population of 431 patients. Electronic records were reviewed for reproductive function, assessed by current menstruation, pregnancy (in the absence of POI diagnosis), reproductive hormone measurements, pubertal progression, or diagnosis of POI. Patients on hormonal contraception (other than for treatment of POI or panhypopituitarism with no history of gonadatoxic treatment) were excluded from analysis (n = 9). Analysis on remaining 422 patients was carried out using the Kaplan-Meier methods, with POI as the defined event, and Cox proportional hazards model. MAIN RESULTS AND THE ROLE OF CHANCE: In the study population of 431 patients, median ages at diagnosis and analysis were 9.8 and 22.2 years, respectively. Reproductive outcomes were unavailable in 142 patients; the assumption was made that these patients did not have POI, but a subanalysis excluding these patients was also performed. Of the 422 patients aged >12 at analysis and not taking hormonal contraception, OTC was offered to 37 patients and successfully performed in 25 patients. Of the 37 patients offered OTC (one at time of relapse), nine (24.3%) developed POI. Of the 386 not offered OTC, 11 (2.9%) developed POI. The probability of developing POI was significantly higher in those offered OTC (hazard ratio [HR] 8.7 [95% CI 3.6-21]; P < 0.0001), even when those patients with unknown outcomes were excluded from the analysis (HR 8.1 [95% CI 3.4-20]; P < 0.001). All patients offered OTC who developed POI did so after treatment for primary disease; in those not offered OTC, five patients (45.5%) developed POI after treatment for disease relapse. LIMITATIONS, REASONS FOR CAUTION: A significant number of patients had unknown reproductive outcomes; many of these patients were engaged in ongoing follow-up but did not have documented reproductive assessment. This may have introduced bias to the analysis and highlights the need for reproductive follow-up as part of routine cancer aftercare. In addition, the relatively young age of the patient population and short duration of follow-up in some cases demonstrates the need for ongoing follow-up of this cohort. WIDER IMPLICATIONS OF THE FINDINGS: The prevalence of POI after childhood cancer is low, but the Edinburgh selection criteria remain a robust tool for selecting those at high risk at the time of diagnosis, to offer OTC appropriately. However, disease relapse necessitating more intensive treatments remains a challenge. This study additionally highlights the importance of routine assessment and documentation of reproductive status in haematology/oncology follow-up. STUDY FUNDING/COMPETING INTEREST(S): K.D. is supported by a CRUK grant (C157/A25193). This work was undertaken in part in the MRC Centre for Reproductive Health, (supported by MRC grant MR/N022556/1). R.A.A. has received consulting fees from Ferring and Roche Diagnostics; payment from Merck and IBSA for educational events; and laboratory materials from Roche Diagnostics. The other authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Duffin K, Howie R, Kelsey TW, et al. Long-term follow-up to assess criteria for ovarian tissue cryopreservation for fertility preservation in young women and girls with cancer. Hum Reprod. 2023. PMID: 37011633. doi:10.1093/humrep/dead060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。